• Vaccine Name: V-LSG/N
• Target Pathogen: Lassa Fever Virus
• Target Disease: Lassa fever
• Vaccine Ontology ID: VO_0004083
• Type: Vaccina virus
• Preparation: V-LSG is a vaccinia viruses expressing the S-segment Lassa glycoprotein (Fisher-Hoch et al., 2000).
• Virulence:
• Description: V-LSG/N is a vaccinia viruses expressing the full length glycoprotein and nucleoprotein in the same construct (Fisher-Hoch et al., 2000).

Monkey Response

• Host Strain: Rhesus
• Vaccination Protocol: Two animals were vaccinated. Each animal received a single vaccination consisting of 0.2 ml of vaccine given intradermally and simultaneously at four separate sites (each forearm and the lateral aspect of each thigh) at a dilution which delivered to each animal a total dose of 10^9 PFU. All animals were challenged subcutaneously with 10^3 to 10^4 PFU of the Josiah strain of Lassa virus in 0.5 ml of phosphate-buffered saline within 36 to 700 days
• Persistence: The latest day on which virus could be recovered from serum was day 14, and that from tissues was day 21. Evidence for persistence elsewhere in tissues or fluids in survivors could not be found by cocultivation of tissues taken up to 112 days following challenge. However, autopsy and biopsy material examined by RT-PCR revealed that viral RNA could be detected at least 112 days after challenge (Fisher-Hoch et al., 2000).
• Side Effects: None noted
• Efficacy: The results of this experiment show that V-LSG/N provides effective means of protecting monkeys against the Lassa virus (Fisher-Hoch et al., 2000).
• Description: Both of the animals survived when challenged with the Lassa virus. These animals showed no significant mean virus titers when compared with those of unvaccinated animals (Fisher-Hoch et al., 2000).